In today’s recent session, 0.8 million shares of the Alpine Immune Sciences Inc (NASDAQ:ALPN) have been traded, and its beta is 0.92. Most recently the company’s share price was $64.46, and it changed around -$0.09 or -0.13% from the last close, which brings the market valuation of the company to $4.23B. ALPN at last check was trading at a discount to its 52-week high of $64.57, offering almost -0.17% off that amount. The share price’s 52-week low was $6.71, which indicates that the recent value has risen by an impressive 89.59% since then. We note from Alpine Immune Sciences Inc’s average daily trading volume that its 3-month average coming to 2.20 million.
Alpine Immune Sciences Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 2.75. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ALPN as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Alpine Immune Sciences Inc is expected to report earnings per share of -$0.41 for the current quarter.
Alpine Immune Sciences Inc (NASDAQ:ALPN) trade information
Instantly ALPN has been showing red trend so far today with a performance of -0.13% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 238.22% year-to-date, but still up 0.07% over the last five days. On the other hand, Alpine Immune Sciences Inc (NASDAQ:ALPN) is 54.96% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $55, which translates to bulls needing to decrease their stock price by -17.2% from its current value. Analyst projections state that ALPN is forecast to be at a low of $44 and a high of $65.
Alpine Immune Sciences Inc (ALPN) estimates and forecasts
Alpine Immune Sciences Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 542.72 percent over the past six months and at a -171.88% annual growth rate that is well below the industry average of 10.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -46.40% in revenue this quarter, and will report a decrease of -55.60% in the next quarter. The year-over-year growth rate is expected to be -73.40%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $3.52 million in revenue for the current quarter. 6 analysts expect Alpine Immune Sciences Inc to make $3.49 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $9.39 million and -$ respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -62.50%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 24.56%.
